17:59 IST
NSE
Regulatory Approval
Lupin Regulatory Approval
Lupin received U.S. FDA approval for Sodium Zirconium Cyclosilicate for Oral Suspension. The drug treats hyperkalemia in adults.
Lupin Ltd
Lupin Ltd news stories on ALFA NewsRead the news →- Share price
- ₹2,006.90
- Market cap
- ₹91,774 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 16.6×Sector 47.4×
- Promoter holding
- 46.85%-0.01% QoQ
- FII holding
- 22.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.